In a Good Place
Water Tower Research hosted InMed's CEO and President Eric A. Adams for a fireside chat on May 23. Our discussion included an overview of rare cannabinoids, InMed's pharmaceutical development programs, the importance of its BayMedica subsidiary, the company's financing strategy, and upcoming catalysts. This report contains a transcript of the conversation, which can be accessed on demand. InMed is a rare cannabinoids company, not a cannabis company. While rare cannabinoids are typically associated with the cannabis plant, InMed has nothing do with the plant. What InMed does is replicate the chemical structures of the cannabinoids using synthetic chemistry. The company is at the forefront of the research and development of rare non-psychoactive cannabinoids and related analogs for therapeutic use...
Water Tower Research is built on the foundation of democratizing information flow. We bridge the growing information gap between companies and investors through our investor engagement strategies and open-access research platform.
Our research analysts are Wall Street veterans with the experience and knowledge to work with companies and investors in tandem. We provide access to the information and content that anchors the due diligence process for both professional money managers and individual investors. We leverage traditional research distribution channels and the best of modern digital strategies and tactics to amplify this information flow globally to engage all categories of investors and stakeholders.
Information flow is the foundation for creating investor awareness, knowledge, and engagement. Our mission is to help companies and investors have the tools they need and achieve their goals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.